Test Price
6,000 AED✅ Home Collection Available
Comprehensive Tumor Panel 270 Genes + PD‑L1 in UAE | 6000 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 certified processing. Premium Logistics: Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Clinical Guidance: Telephonic post-test clinical guidance for result interpretation. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genomic profiling test simultaneously evaluates 270 cancer‑associated genes and PD‑L1 protein expression, leveraging Next‑Generation Sequencing (NGS) and immunohistochemistry (IHC) to guide targeted therapy, immunotherapy, and clinical trial eligibility. It serves as a cornerstone of precision oncology for solid tumours in the UAE. Tumour tissue is obtained via image‑guided core needle biopsy or archival FFPE block retrieval under sterile hospital conditions.
| Feature | Our Test (NGS + IHC) | Standard 50‑Gene Panel (PCR‑based) |
|---|---|---|
| Genes Analysed | 270 + PD‑L1 | 50 |
| Technology | NGS with PD‑L1 IHC | Real‑time PCR / FISH |
| Diagnostic Sensitivity | 99.9% | ~94% |
| Turnaround Time | 10–12 working days | 14–21 working days |
| Therapy Guidance | Comprehensive – targeted & immunotherapy | Limited targeted therapy only |
Physician Insight & Safety Protocols
"As a specialist in diagnostic radiology, I emphasize that genomic results must always be correlated with imaging, pathology, and full patient history. This panel opens the door to truly personalised cancer care, but it is not a standalone diagnostic tool. Your multidisciplinary team will interpret the findings to design the safest, most effective plan." – Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Important Advisory on Medication Continuity
Continue all prescribed treatments unless explicitly advised otherwise by your treating oncologist. Biomarker results from this panel complement, not replace, your physician's clinical recommendations.
Exclusion Criteria & Red Flags
- Active, uncontrolled infection at the intended biopsy site.
- Severe coagulopathy (e.g., INR > 1.5) unless haematologically cleared for biopsy.
- Inability to provide informed consent or comply with post‑procedure monitoring.
Seek immediate medical attention if you experience:
- Excessive bleeding, swelling, or purulent discharge post‑biopsy.
- Fever > 38.5°C or signs of systemic infection.
- Severe pain unrelieved by standard analgesia.
Patient FAQ & Clinical Guidance
1. What exactly does the Comprehensive Tumor Panel 270 Genes + PD‑L1 test measure?
This assay simultaneously sequences 270 genes for mutations, copy number alterations, and gene fusions while quantifying PD‑L1 protein expression on tumour cells. DNA extracted from your tumour biopsy is analysed via NGS alongside immunohistochemical staining to detect actionable biomarkers, helping oncologists select FDA‑approved therapies or match to clinical trials.
2. Who should consider undergoing this comprehensive genomic profiling?
Patients with advanced or metastatic solid tumours, rare cancers, or those who have exhausted standard therapy lines benefit most. Individuals with a strong family history of cancer seeking risk stratification may also discuss this option with a genetic counsellor or oncologist.
3. How is the biopsy sample collected and what pre‑test preparation is required?
A small tumour tissue sample is obtained via image‑guided core needle biopsy performed in a hospital setting. No fasting or medication changes are required beforehand. Our clinical team coordinates scheduling and reviews pre‑procedure information telephonically to ensure safety. All samples are transported via secure medical courier under cold‑chain conditions.
4. How long does it take to receive results and how will they be delivered?
Results are typically available within 10–12 working days from sample receipt. A comprehensive molecular pathology report is delivered electronically to your treating physician, followed by a telephonic clinical guidance session to explain key findings and therapeutic implications.
5. Will my health insurance cover the cost of this test?
Coverage depends on your specific insurance policy. Our billing team can verify your direct billing eligibility via WhatsApp at +971 54 548 8731. Self‑pay options are also available at the listed price.
UAE Regulatory & Data Privacy Adherence
Your genomic data and personal health information are protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All sample handling and reporting procedures comply with DHA standards for diagnostic genomics. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE maintains ISO 9001:2015 certification and adheres to strict confidentiality protocols for all molecular data.
Clinical & Logistical Metadata
| Test Name | Comprehensive Tumor Panel 270 Genes + PD‑L1 |
| Price (AED) | 6,000 |
| Turnaround Time | 10–12 working days |
| Sample Type / Matrix | Solid tumour tissue – fresh core needle biopsy or archival FFPE block |
| Methodology Used | Next‑Generation Sequencing (NGS) + Immunohistochemistry (IHC) |
| ICD-10-CM Code | C80.1 |
| LOINC Code | 91854-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians